Genenta Science (GNTA) Stock Price, News & Analysis

Company Overview

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Key Stats

• Today's Range: $3.76 to $3.88
• 50-Day Range: $3.56 to $5.01
• 52-Week Range: $2.79 to $7.28
• Volume: 853 shs
• Average Volume: 15,011 shs
• Market Capitalization: $70.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Buy

Genenta Science Stock Analysis - MarketRank™

Genenta Science scored higher than 55% of companies evaluated by MarketBeat, and ranked 500th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Genenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genenta Science has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.

Price to Book Value per Share Ratio

Genenta Science has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Genenta Science has been sold short.

Short Interest Ratio / Days to Cover

Genenta Science has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genenta Science has recently decreased by 31.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genenta Science does not currently pay a dividend.

Dividend Growth

Genenta Science does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the float of Genenta Science has been sold short.

Short Interest Ratio / Days to Cover

Genenta Science has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genenta Science has recently decreased by 31.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.96

News Sentiment

Genenta Science has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Genenta Science this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genenta Science insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.13% of the stock of Genenta Science is held by institutions.

GNTA Stock Analysis - Frequently Asked Questions

How have GNTA shares performed this year?

Genenta Science's stock was trading at $4.35 on January 1st, 2025. Since then, GNTA shares have decreased by 10.9% and is now trading at $3.8750.
View the best growth stocks for 2025 here.

When did Genenta Science IPO?

Genenta Science (GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.

Who are Genenta Science's major shareholders?

Top institutional shareholders of Genenta Science include Allianz SE (1.28%) and Algebris UK Ltd (0.55%).

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genenta Science own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP).

Company Calendar

• Today: 6/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNTA
• CIK: 1838716
• Web: www.genenta.com
• Phone: 39-02-2643-4681
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +545.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.31
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.21 per share
• Price / Book: 3.20

Miscellaneous

• Outstanding Shares: 18,290,000
• Free Float: 12,988,000
• Market Cap: $70.87 million
• Optionable: Not Optionable
• Beta: 0.73